FLT4
Appearance
(Redirected fromVEGFR3)
Fms-related tyrosine kinase 4,also known asFLT4,is aproteinwhich in humans is encoded by theFLT4gene.[5][6]
This gene encodes atyrosine kinasereceptor forvascular endothelial growth factorsCandD.The protein is thought to be involved inlymphangiogenesisand maintenance of the lymphatic endothelium. Mutations in this gene cause hereditarylymphedematype IA.[5]
Interactions
[edit]FLT4 has been shown tointeractwithSHC1.[7][8][9]
See also
[edit]References
[edit]- ^abcGRCh38: Ensembl release 89: ENSG00000037280–Ensembl,May 2017
- ^abcGRCm38: Ensembl release 89: ENSMUSG00000020357–Ensembl,May 2017
- ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ab"Entrez Gene: FLT4 fms-related tyrosine kinase 4".
- ^Galland F, Karamysheva A, Mattei MG, Rosnet O, Marchetto S, Birnbaum D (June 1992). "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene".Genomics.13(2): 475–8.doi:10.1016/0888-7543(92)90277-Y.PMID1319394.
- ^Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K (December 1994). "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors".Oncogene.9(12): 3545–55.PMID7970715.
- ^Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (January 1999)."Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling".Oncogene.18(2): 507–14.doi:10.1038/sj.onc.1202315.PMID9927207.
- ^Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP (May 1996)."Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase".The Journal of Biological Chemistry.271(22): 12956–63.doi:10.1074/jbc.271.22.12956.PMID8662748.
Further reading
[edit]- Petrova TV, Makinen T, Alitalo K (November 1999). "Signaling via vascular endothelial growth factor receptors".Experimental Cell Research.253(1): 117–30.doi:10.1006/excr.1999.4707.PMID10579917.
- Aprelikova O, Pajusola K, Partanen J, Armstrong E, Alitalo R, Bailey SK, McMahon J, Wasmuth J, Huebner K, Alitalo K (February 1992). "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter".Cancer Research.52(3): 746–8.PMID1310071.
- Galland F, Karamysheva A, Mattei MG, Rosnet O, Marchetto S, Birnbaum D (June 1992). "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene".Genomics.13(2): 475–8.doi:10.1016/0888-7543(92)90277-Y.PMID1319394.
- Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K (October 1992). "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines".Cancer Research.52(20): 5738–43.PMID1327515.
- Fournier E, Dubreuil P, Birnbaum D, Borg JP (September 1995). "Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor".Oncogene.11(5): 921–31.PMID7675451.
- Pajusola K, Aprelikova O, Armstrong E, Morris S, Alitalo K (November 1993). "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts".Oncogene.8(11): 2931–7.PMID7692369.
- Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K (December 1994). "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors".Oncogene.9(12): 3545–55.PMID7970715.
- Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Rosnet O, Birnbaum D (May 1993). "The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor".Oncogene.8(5): 1233–40.PMID8386825.
- Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP (May 1996)."Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase".The Journal of Biological Chemistry.271(22): 12956–63.doi:10.1074/jbc.271.22.12956.PMID8662748.
- Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI (March 1996)."Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4".Proceedings of the National Academy of Sciences of the United States of America.93(5): 1988–92.Bibcode:1996PNAS...93.1988L.doi:10.1073/pnas.93.5.1988.PMC39896.PMID8700872.
- Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K (December 1996). "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development".Development.122(12): 3829–37.doi:10.1242/dev.122.12.3829.PMID9012504.
- Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (January 1998)."Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)".Proceedings of the National Academy of Sciences of the United States of America.95(2): 548–53.Bibcode:1998PNAS...95..548A.doi:10.1073/pnas.95.2.548.PMC18457.PMID9435229.
- Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM, Finegold DN (December 1998). "Hereditary lymphedema: evidence for linkage and genetic heterogeneity".Human Molecular Genetics.7(13): 2073–8.doi:10.1093/hmg/7.13.2073.PMID9817924.
- Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (January 1999)."Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling".Oncogene.18(2): 507–14.doi:10.1038/sj.onc.1202315.PMID9927207.
- Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN (June 2000). "Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema".Nature Genetics.25(2): 153–9.doi:10.1038/75997.PMID10835628.S2CID38445644.
- Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M (August 2000)."Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase".American Journal of Human Genetics.67(2): 295–301.doi:10.1086/303019.PMC1287178.PMID10856194.
- Wang JF, Zhang XF, Groopman JE (November 2001)."Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration".The Journal of Biological Chemistry.276(45): 41950–7.doi:10.1074/jbc.M101370200.PMID11553610.
- Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, Achen MG (November 2001)."Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis".The Journal of Biological Chemistry.276(47): 44307–14.doi:10.1074/jbc.M106188200.PMID11574540.
- Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA (March 2002). "Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma".Genes, Chromosomes & Cancer.33(3): 295–303.doi:10.1002/gcc.10028.PMID11807987.S2CID33428561.
External links
[edit]This article incorporates text from theUnited States National Library of Medicine,which is in thepublic domain.